MEK inhibitor (selumetinib) is a potent, orally active inhibitor of MAPK/ERK pathway. It is important to develop an accurate and robust method indicative of RAS pathway activity to stratify potential patients who can benefit from selumetinib treatment in gastric cancer (GC). First, we surveyed the sensitivity to selumetinib in a panel of 22 GC cell lines and correlated with MEK signature to selumetinib sensitivity. Next, we analyzed MEK signature via nanostring assay in two Asian cohorts using clinical samples ( = 218) and then performed a correlative analysis with MEK signature status and genotype in GC. MEK signature was predictive of response of selumetinib in GC cell lines regardless of mutation status. The proportion of high MEK signature by nanostring assay was 6.9% and the proportion of high MEK signature was significantly higher in altered group in a Korean cohort. None of altered cases belonged to high MEK signature group. MEK high signature was more prevalent in intestinal type by Lauren classification. The correlation between MEK signature, alteration and treatment response to selumetinib should be validated in prospective clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746083 | PMC |
| http://dx.doi.org/10.18632/oncotarget.18182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Synergistic Effect of IGF1-R Inhibitor AEW541 on Imatinib Inducing SUP-B15 Cell Death].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Blood Diseases Institute, Xuzhou Medical University, Department of Hematology, The Affiliated Hospital of Xuzhou Medical University.
Objective: To explore whether Ph acute lymphoblastic leukemia (ALL) cell line SUP-B15 treated with imatinib occurs a tolerant status charactered by cell proliferation suppression but apoptotic resistance, then evaluate whether IGF1-R inhibitor AEW541 can break this tolerance, and further explain its mechanisms.
Methods: SUP-B15 cells were treated with different concentrations of imatinib or AEW541. Cell proliferation was assayed by Deep Blue, and apoptotic cells were determined by Annexin V/7-AAD staining.
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis.
Blood
December 2024
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States.
We previously demonstrated that reduced intrinsic electron transport chain (ETC) activity predicts and promotes sensitivity to the BCL-2 antagonist, venetoclax (Ven) in multiple myeloma (MM). Heme, an iron-containing prosthetic group, and metabolite is fundamental to maintaining ETC activity. Interrogation of the CD2 subgroup of MM from the CoMMpass trial (NCT01454297), which can be used as a proxy for Ven-sensitive MM (VS MM), shows reduced expression of the conserved heme biosynthesis pathway gene signature.
View Article and Find Full Text PDFThe ability of cancer cells to alter their identity, known as lineage plasticity, is crucial for tumor progression and therapy resistance. In lung adenocarcinoma (LUAD), tumor progression is characterized by a gradual loss of lineage fidelity and the emergence of non-pulmonary identity programs. This can lead to hybrid-identity (hybrid-ID) states in which developmentally incompatible identity programs are co-activated within individual cells.
View Article and Find Full Text PDFPhosphoproteomic response to epidermal growth factor in native rat inner medullary collecting duct.
Am J Physiol Renal Physiol
January 2025
Epithelial Systems Biology Laboratory, Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States.
Epidermal growth factor (EGF) has important effects in the renal collecting duct to regulate salt and water transport. To identify elements of EGF-mediated signaling in the rat renal inner medullary collecting duct (IMCD), we carried out phosphoproteomic analysis. Biochemically isolated rat IMCD suspensions were treated with 1 µM of EGF or vehicle for 30 min.
View Article and Find Full Text PDFAnalysis of Modular Hub Genes and Therapeutic Targets across Stages of Non-Small Cell Lung Cancer Transcriptome.
Genes (Basel)
September 2024
School of Chemical, Biological, and Materials Engineering and Sciences, Mapúa University, Manila City 1002, Philippines.
Article Synopsis
- - Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and is categorized into four progress stages; this study used Weighted Gene Co-expression Network Analysis (WGCNA) to understand its molecular mechanisms and find treatment targets.
- - Eight preserved gene modules were identified, linked to key pathways like "Cell cycle" and "Pathways in cancer," with important genes such as PLK1, CDK1, EGFR, and the estrogen receptor ESR1 noted for their roles in tumor growth and survival outcomes.
- - Analysis of drug repurposing highlighted potential therapeutic options, including GW-5074 and olomoucine, which target specific signaling processes, along with other candidates like pinoc
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!